402 related articles for article (PubMed ID: 34268954)
21. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial.
Lu W; Jin XL; Yang C; Du P; Jiang FQ; Ma JP; Yang J; Xie P; Zhang Z
Cancer Biol Ther; 2017 Jun; 18(6):433-438. PubMed ID: 28548587
[TBL] [Abstract][Full Text] [Related]
22. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Jiang Z; Zhou A; Sun Y; Zhang W
BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
[TBL] [Abstract][Full Text] [Related]
23. The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials.
Liu Y; Zhou C; Zhang K; Feng Y; Zhang R
Medicine (Baltimore); 2018 Nov; 97(47):e13259. PubMed ID: 30461630
[TBL] [Abstract][Full Text] [Related]
24. Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma.
Zhou L; Lin J; Wu G; Chen J; Huang X; Zhang S
Drug Des Devel Ther; 2020; 14():1257-1262. PubMed ID: 32280197
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
Wang Z; He T; Yu D; Qin X; Geng A; Yang H
Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
[TBL] [Abstract][Full Text] [Related]
26. [Tegafur/gimeracil/oteracil (Teysuno), by oral administration].
Duh D; Warnez M
J Pharm Belg; 2013 Dec; (4):35-6. PubMed ID: 24449972
[No Abstract] [Full Text] [Related]
27. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
28. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
[TBL] [Abstract][Full Text] [Related]
29. Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
Ye Z; Zeng Y; Wei S; Wang Y; Lin Z; Chen S; Wang Z; Chen S; Chen L
BMC Cancer; 2021 Jun; 21(1):702. PubMed ID: 34126957
[TBL] [Abstract][Full Text] [Related]
30. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Tsujitani S; Fukuda K; Kaibara N
Gastric Cancer; 2003; 6 Suppl 1():50-7. PubMed ID: 12775021
[TBL] [Abstract][Full Text] [Related]
32. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
[TBL] [Abstract][Full Text] [Related]
33. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.
He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH
Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
Luo H; Yu Z; Gao H; Guan C; Xu M
J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
[TBL] [Abstract][Full Text] [Related]
35. [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Yagi M; Watanabe S; Yoshino S; Hazama S; Suga T; Nakazawa S
Gan To Kagaku Ryoho; 2010 Mar; 37(3):457-62. PubMed ID: 20332683
[TBL] [Abstract][Full Text] [Related]
36. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract][Full Text] [Related]
37. Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Otsuka H; Fujii T; Toh U; Iwakuma N; Takahashi R; Mishima M; Takenaka M; Kakuma T; Tanaka M; Shirouzu K
Breast Cancer; 2015 Jul; 22(4):335-42. PubMed ID: 23827973
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients.
Wang T; Zhang SF; Qiu MQ; Li QL
Cancer Radiother; 2016 May; 20(3):181-6. PubMed ID: 27068497
[TBL] [Abstract][Full Text] [Related]
40. Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer.
Yang H; Sui Y; Guo X; Tan X; Li Y; Wang M
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1148-S1151. PubMed ID: 30539861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
